Caldera Therapeutics

Cambridge, United States

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

Jan 2026

Series A

Biopharma Biotechnology Life Science

Top Investors

Lilly Asia VenturesJanus Henderson InvestorsWellington ManagementOmega FundsAtlas Venture

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Caldera Therapeutics

Who are Caldera Therapeutics's investors?

Caldera Therapeutics's investors include Lilly Asia Ventures, Janus Henderson Investors, Wellington Management, Omega Funds, Atlas Venture.

Where is Caldera Therapeutics headquartered?

Caldera Therapeutics is headquartered in Cambridge, United States.

What does Caldera Therapeutics do?

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

What stage is Caldera Therapeutics at?

Caldera Therapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated January 14, 2026.

MLA

"Caldera Therapeutics — Funding & Investors." VCBacked, January 14, 2026, https://www.vcbacked.co/company/caldera-therapeutics. Accessed July 1, 2026.

APA

VCBacked. (2026). Caldera Therapeutics — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/caldera-therapeutics

Wikipedia (cite web)

{{cite web |title=Caldera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/caldera-therapeutics |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated January 14, 2026.